OncoMatch/Clinical Trials/NCT07291076

A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)

Is NCT07291076 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments including Pumitamig and Ipilimumab for hepatocellular carcinoma (hcc).

Phase 1/2RecruitingBristol-Myers SquibbNCT07291076Data as of May 2026

Treatment: Pumitamig · Ipilimumab · Atezolizumab · Bevacizumab — The purpose of this study is to evaluate the safety and tolerability of Pumitamig alone or in combination with Ipilimumab in participants with first-line advanced or unresectable Hepatocellular Carcinoma (HCC)

Check if I qualify

Extracted eligibility criteria

Cancer type

Hepatocellular Carcinoma

Performance status

ECOG 0–1(Restricted strenuous activity)

Prior therapy

No prior treatment (treatment-naive required)

Max 0 prior lines

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

Local Institution - 0070 · Los Angeles, California
Local Institution - 0107 · Chicago, Illinois
John Theurer Cancer Center at Hackensack University Medical Center · Hackensack, New Jersey
Local Institution - 0100 · Great Neck, New York
Local Institution - 0080 · Portland, Oregon

Showing up to 5 US sites. See all sites on ClinicalTrials.gov →

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify